Suppr超能文献

非活动期克罗恩病患者的小肠细菌过度生长:硫唑嘌呤和生物治疗的影响

Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment.

作者信息

Sánchez-Montes Cristina, Ortiz Vicente, Bastida Guillermo, Rodríguez Ester, Yago María, Beltrán Belén, Aguas Mariam, Iborra Marisa, Garrigues Vicente, Ponce Julio, Nos Pilar

机构信息

Cristina Sánchez-Montes, Vicente Ortiz, Guillermo Bastida, Ester Rodríguez, María Yago, Belén Beltrán, Mariam Aguas, Marisa Iborra, Vicente Garrigues, Julio Ponce, Pilar Nos, Gastroenterology Unit, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain.

出版信息

World J Gastroenterol. 2014 Oct 14;20(38):13999-4003. doi: 10.3748/wjg.v20.i38.13999.

Abstract

AIM

To investigate the influence of thiopurines and biological drugs on the presence of small intestinal bacterial overgrowth (SIBO) in patients with inactive Crohn's disease (CD).

METHODS

This was a prospective study in patients with CD in remission and without corticosteroid treatment, included consecutively from 2004 to 2010. SIBO was investigated using the hydrogen glucose breath test.

RESULTS

One hundred and seven patients with CD in remission were included. Almost 58% of patients used maintenance immunosuppressant therapy and 19.6% used biological therapy. The prevalence of SIBO was 16.8%. No association was observed between SIBO and the use of thiopurine Immunosuppressant (12/62 patients), administration of biological drugs (2/21 patients), or with double treatment with an anti-tumor necrosis factor drugs plus thiopurine (1/13 patients). Half of the patients had symptoms that were suggestive of SIBO, though meteorism was the only symptom that was significantly associated with the presence of SIBO on univariate analysis (P < 0.05). Multivariate analysis revealed that the presence of meteorism and a fistulizing pattern were associated with the presence of SIBO (P < 0.05).

CONCLUSION

Immunosuppressants and/or biological drugs do not induce SIBO in inactive CD. Fistulizing disease pattern and meteorism are associated with SIBO.

摘要

目的

研究硫唑嘌呤和生物制剂对缓解期克罗恩病(CD)患者小肠细菌过度生长(SIBO)的影响。

方法

这是一项对2004年至2010年连续纳入的缓解期CD患者且未接受皮质类固醇治疗的前瞻性研究。采用氢葡萄糖呼气试验检测SIBO。

结果

纳入107例缓解期CD患者。近58%的患者使用维持性免疫抑制治疗,19.6%的患者使用生物治疗。SIBO的患病率为16.8%。未观察到SIBO与硫唑嘌呤免疫抑制剂的使用(62例患者中的12例)、生物制剂的使用(21例患者中的2例)或抗肿瘤坏死因子药物加硫唑嘌呤联合治疗(13例患者中的1例)之间存在关联。一半的患者有提示SIBO的症状,尽管在单因素分析中,腹胀是唯一与SIBO存在显著相关的症状(P<0.05)。多因素分析显示,腹胀的存在和瘘管形成模式与SIBO的存在相关(P<0.05)。

结论

免疫抑制剂和/或生物制剂不会在缓解期CD患者中诱发SIBO。瘘管形成疾病模式和腹胀与SIBO相关。

相似文献

1
Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment.
World J Gastroenterol. 2014 Oct 14;20(38):13999-4003. doi: 10.3748/wjg.v20.i38.13999.
3
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
World J Gastroenterol. 2014 Aug 7;20(29):9675-90. doi: 10.3748/wjg.v20.i29.9675.
4
Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience.
Dig Dis Sci. 2019 Mar;64(3):875-879. doi: 10.1007/s10620-018-5381-0. Epub 2018 Dec 12.
5
Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response.
Scand J Gastroenterol. 2015;50(11):1376-81. doi: 10.3109/00365521.2015.1050691. Epub 2015 May 19.
8
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Gastroenterology. 2019 Jan;156(1):36-42. doi: 10.1053/j.gastro.2018.08.043. Epub 2018 Sep 7.
9
Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):689-700. doi: 10.1586/17474124.2013.842895.
10
Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Dig Dis Sci. 2021 May;66(5):1650-1657. doi: 10.1007/s10620-020-06427-8. Epub 2020 Jun 26.

引用本文的文献

1
Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies.
Contemp Oncol (Pozn). 2025;29(1):11-21. doi: 10.5114/wo.2025.148643. Epub 2025 Mar 18.
2
Prevalence and predictors of small intestinal bacterial overgrowth in inflammatory bowel disease: a meta-analysis.
Front Med (Lausanne). 2025 Jan 21;11:1490506. doi: 10.3389/fmed.2024.1490506. eCollection 2024.
5
Epidemiology of small intestinal bacterial overgrowth.
World J Gastroenterol. 2023 Jun 14;29(22):3400-3421. doi: 10.3748/wjg.v29.i22.3400.
6
The interplay between bile acids and mucosal adaptive immunity.
PLoS Pathog. 2023 Jun 22;19(6):e1011356. doi: 10.1371/journal.ppat.1011356. eCollection 2023 Jun.
10
Small intestinal bacterial overgrowth in inflammatory bowel disease.
Indian J Gastroenterol. 2022 Feb;41(1):23-29. doi: 10.1007/s12664-021-01235-y. Epub 2022 Jan 15.

本文引用的文献

1
Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.
Clin Gastroenterol Hepatol. 2013 May;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011. Epub 2012 Dec 24.
2
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.
J Crohns Colitis. 2010 Feb;4(1):7-27. doi: 10.1016/j.crohns.2009.12.003. Epub 2010 Jan 15.
3
Safety profile of IBD therapeutics: infectious risks.
Gastroenterol Clin North Am. 2009 Dec;38(4):691-709. doi: 10.1016/j.gtc.2009.07.005.
5
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Aliment Pharmacol Ther. 2009 Mar 30;29 Suppl 1:1-49. doi: 10.1111/j.1365-2036.2009.03951.x.
6
Management of Crohn's disease in adults.
Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484. doi: 10.1038/ajg.2008.168. Epub 2009 Jan 6.
7
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.
8
Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Gastroenterol Clin North Am. 2006 Dec;35(4):837-55. doi: 10.1016/j.gtc.2006.09.008.
10
Small bowel bacterial overgrowth: presentation, diagnosis, and treatment.
Curr Gastroenterol Rep. 2003 Oct;5(5):365-72. doi: 10.1007/s11894-003-0048-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验